Anti-inflammatory therapies in bronchiectasis

Smith, D. J., Chang, A. B. and Bell, S. C. (2011). Anti-inflammatory therapies in bronchiectasis. In R.A. Floto and C.S. Haworth (Ed.), Bronchiectasis (pp. 233-238) Lausanne, Switzerland: European Respiratory Society. doi:10.1183/1025448x.100004510

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Smith, D. J.
Chang, A. B.
Bell, S. C.
Title of chapter Anti-inflammatory therapies in bronchiectasis
Title of book Bronchiectasis
Place of Publication Lausanne, Switzerland
Publisher European Respiratory Society
Publication Year 2011
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1183/1025448x.100004510
Open Access Status Not Open Access
Series European Respiratory Monograph
ISBN 9781849840118
ISSN 0904-1850
Editor R.A. Floto
C.S. Haworth
Volume number 52
Chapter number 15
Start page 233
End page 238
Total pages 6
Total chapters 18
Language eng
Formatted Abstract/Summary
Although the use of anti-inflammatory therapies in bronchiectasis remains an attractive proposition, there is currently insufficient evidence to support the use of inhaled and oral corticosteroids, non-steroidal anti-inflammatory drugs and macrolides. Individual patient trials may be warranted for inhaled corticosteroids and macrolides. It is hoped that recently completed and ongoing randomised control trials of macrolides will better define the use and safety in bronchiectasis. There remains an urgent need to perform adequately powered multicentre trials of other potentially useful therapies.

It is anticipated that specialised bronchiectasis clinics will provide greater opportunities to study disease epidemiology and pathogenesis and allow better definition of study population for inclusion within future trials. There is a need for a more defined study population and a widely accepted definition of a pulmonary exacerbation in bronchiectasis which may be applied uniformly across studies to allow direct comparison of study outcomes. Finally, care should be taken to ensure adequate follow-up to detect potential adverse effects of new therapies, particularly on microbial resistance patterns.
Keyword Ant-inflammatory therapy
Inhaled corticosteroids
Q-Index Code BX
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Quarterly monographic series - title: "Bronchiectasis"

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in Thomson Reuters Web of Science Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 21 Dec 2011, 23:54:13 EST by Jane Medhurst on behalf of Child Health Research Centre